A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis
Author:
Affiliation:
1. pH Associates Ltd (an OPEN Health Company), Marlow, UK;
2. Bladon Associates, Oxford, UK;
3. The Stats People, Sevenoaks, Kent, UK;
4. Novartis, Frimley, Surrey, UK
Funder
Novartis Pharmaceuticals UK Limited
Publisher
Informa UK Limited
Subject
Health Policy
Link
https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1336099
Reference26 articles.
1. National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. London, UK: NICE guidelines [CG186]. NICE; 2014
2. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis
3. Preferred Features of Oral Treatments and Predictors of Non-Adherence: Two Web-Based Choice Experiments in Multiple Sclerosis Patients
4. Patient Preferences for Attributes of Multiple Sclerosis Disease-Modifying Therapies
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption;Journal of Neurology;2024-04-14
2. Shifting from the treat-to-target to the early highly effective treatment approach in patients with multiple sclerosis – real-world evidence from Germany;Therapeutic Advances in Neurological Disorders;2024-01
3. Multiple sclerosis: time for early treatment with high-efficacy drugs;Journal of Neurology;2023-10-18
4. Individual Differences in the Patient Experience of Relapsing Multiple Sclerosis (RMS): A Multi-Country Qualitative Exploration of Drivers of Treatment Preferences Among People Living with RMS;The Patient - Patient-Centered Outcomes Research;2023-04-05
5. To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis;Journal of Medical Economics;2023-01-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3